ZA201003434B - Method of treating arthritis - Google Patents

Method of treating arthritis

Info

Publication number
ZA201003434B
ZA201003434B ZA2010/03434A ZA201003434A ZA201003434B ZA 201003434 B ZA201003434 B ZA 201003434B ZA 2010/03434 A ZA2010/03434 A ZA 2010/03434A ZA 201003434 A ZA201003434 A ZA 201003434A ZA 201003434 B ZA201003434 B ZA 201003434B
Authority
ZA
South Africa
Prior art keywords
treating arthritis
arthritis
treating
Prior art date
Application number
ZA2010/03434A
Other languages
English (en)
Inventor
Philip Bardwell
Tariq Ghayur
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of ZA201003434B publication Critical patent/ZA201003434B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2010/03434A 2007-11-16 2010-05-14 Method of treating arthritis ZA201003434B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98847907P 2007-11-16 2007-11-16
PCT/US2008/083478 WO2009064938A1 (en) 2007-11-16 2008-11-14 Method of treating arthritis

Publications (1)

Publication Number Publication Date
ZA201003434B true ZA201003434B (en) 2011-10-26

Family

ID=40291332

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/03434A ZA201003434B (en) 2007-11-16 2010-05-14 Method of treating arthritis

Country Status (14)

Country Link
US (2) US20090176785A1 (OSRAM)
EP (1) EP2231159A1 (OSRAM)
JP (2) JP5450434B2 (OSRAM)
KR (1) KR101585848B1 (OSRAM)
CN (1) CN101969951B (OSRAM)
AU (1) AU2008322595B2 (OSRAM)
CA (1) CA2705294C (OSRAM)
DO (1) DOP2013000169A (OSRAM)
IL (2) IL205501A (OSRAM)
MX (1) MX2010005395A (OSRAM)
NZ (2) NZ601350A (OSRAM)
RU (2) RU2526201C2 (OSRAM)
WO (1) WO2009064938A1 (OSRAM)
ZA (1) ZA201003434B (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2957558A3 (en) 2010-03-25 2016-03-02 AbbVie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
NZ608274A (en) 2010-10-29 2015-05-29 Abbvie Inc Solid dispersions containing an apoptosis-inducing agent
SG190361A1 (en) 2010-11-23 2013-06-28 Abbvie Inc Salts and crystalline forms of an apoptosis-inducing agent
MY165884A (en) 2010-11-23 2018-05-18 Abbvie Ireland Unlimited Co Methods of treatment using selective bcl-2 inhibitors
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN111511748B (zh) 2017-08-23 2023-05-02 广州麓鹏制药有限公司 Bcl-2抑制剂
US11903950B2 (en) 2018-08-22 2024-02-20 Newave Pharmaceutical Inc. BCL-2 inhibitors
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
US20220372042A1 (en) 2019-10-03 2022-11-24 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
CA3160091A1 (en) 2019-11-05 2021-05-14 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
CA3173041A1 (en) 2020-02-24 2021-09-02 Guangzhou Lupeng Pharmaceutical Company Ltd. Hot melt extruded solid dispersions containing a bcl2 inhibitor
WO2022140224A1 (en) 2020-12-22 2022-06-30 Newave Pharmaceutical Inc. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
EP0863873B1 (en) * 1995-10-10 1999-11-10 Pfizer Inc. Indole carbamates as leukotriene antagonists
HUP0300235A2 (hu) * 2000-03-21 2003-08-28 The Procter & Gamble Co. Heterociklikus oldalláncot tartalmazó, N-szubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
MX242553B (es) * 2000-10-20 2006-12-06 Eisai Co Ltd Derivados aromaticos que contienen nitrogeno.
GB0217431D0 (en) * 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
CN100591679C (zh) * 2003-07-28 2010-02-24 詹森药业有限公司 苯并咪唑、苯并噻唑和苯并唑衍生物及其作为lta4h调节剂的应用
ES2441206T3 (es) * 2003-09-03 2014-02-03 Raqualia Pharma Inc. Compuestos de fenil o piridilamida como antagonistas de la prostaglandina E2
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
ES2257929B1 (es) * 2004-07-16 2007-05-01 Laboratorios Del Dr. Esteve, S.A. Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos.
EP1888550B1 (en) * 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Apoptosis promoters
US20060276464A1 (en) * 2005-05-13 2006-12-07 Wyeth Diarylsulfone sulfonamides and use thereof
US20080182845A1 (en) * 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection

Also Published As

Publication number Publication date
AU2008322595B2 (en) 2014-01-30
JP2014065716A (ja) 2014-04-17
JP2011503199A (ja) 2011-01-27
RU2010123796A (ru) 2011-12-27
KR101585848B1 (ko) 2016-01-15
CN101969951B (zh) 2012-10-31
IL205501A (en) 2013-08-29
CA2705294C (en) 2016-05-17
CA2705294A1 (en) 2009-05-22
WO2009064938A1 (en) 2009-05-22
WO2009064938A9 (en) 2009-08-06
RU2012143212A (ru) 2014-04-20
US20160101109A1 (en) 2016-04-14
RU2526201C2 (ru) 2014-08-20
NZ601350A (en) 2013-08-30
AU2008322595A1 (en) 2009-05-22
US20090176785A1 (en) 2009-07-09
DOP2013000169A (es) 2013-12-15
JP5667684B2 (ja) 2015-02-12
IL227641A0 (en) 2013-09-30
EP2231159A1 (en) 2010-09-29
MX2010005395A (es) 2010-06-02
JP5450434B2 (ja) 2014-03-26
CN101969951A (zh) 2011-02-09
NZ585085A (en) 2012-08-31
KR20100099172A (ko) 2010-09-10
RU2472509C2 (ru) 2013-01-20
IL205501A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
IL227641A0 (en) Methods for treating arthritis
IL257418A (en) Methods for treating addiction
PT2293816E (pt) Métodos para o tratamento da artrite reumatoide
EP2032131A4 (en) Methods of Treatment
PL2301893T3 (pl) Sposób oczyszczania ścieku
EP2142206A4 (en) METHOD FOR THE TREATMENT OF ISCHEMIC ILLNESSES
EP2350641A4 (en) Methods of Treatment
IL199739A0 (en) Methods for treating psoriasis
IL200769A (en) A method for processing potash
ZA200907349B (en) Method of treating hair
IL199634A0 (en) Method of treating liquid waste
PL2133402T3 (pl) Sposób obróbki błota defekosaturacyjnego
PT2393758E (pt) Processo de tratamento de águas residuais
EP2300496A4 (en) ATHEROSCLEROSIS TREATMENT METHODS
EP2144886A4 (en) METHOD OF TREATING MELANOMA
GB0718684D0 (en) Treatment method
GB0610746D0 (en) Method of treatment
IL205452A0 (en) Methods of treating scleroderma
EP2164515A4 (en) PROCESS FOR TREATING ATOPIC ECZEMA
EP2348858A4 (en) PROCESS FOR THE TREATMENT OF THROMBOCYTOPENIA
IL202002A0 (en) Method of treating diabetes
ZA201007680B (en) Method of treating metalliferrous materials
EP2094385A4 (en) METHOD OF WASTE WATER TREATMENT
EP2306838A4 (en) METHOD FOR THE TREATMENT OF ATHEROSCLEROSIS
ZA200906010B (en) Method for treating and preventing arthritis